It somehow appears they think it is appropriate to retest the samples at this stage (which it is not!) and it appears they are now using "revised interpretation criteria and recombinant antigen WB" to come up with another self-proclaimed specificity rate
, you read in their 2015 response that they have "revised interpretation criteria." The Stricker IgeneX letter, which you referenced, also states the new specificity to be 91.7%. So I am confused as to why you would ask if there are any indications of a revision to criteria.
What may also interest readers here is the letter also points out that according to the Fallon study, the two-tier sensitivity in Lyme patients who remained sick following treatment was only at 48.6%, while Specialty LabB (supposedly IgeneX) had a sensitivity of 89%. As you likely know, @cyclist
, sensitivity and specificity are an essential tandem.
But again, as I have repeatedly suggested, the Lyme community could only benefit if improved diagnostics were pursued by all concerns.